Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.77 and traded as high as $1.06. Brainstorm Cell Therapeutics shares last traded at $1.00, with a volume of 4,979 shares traded.
Brainstorm Cell Therapeutics Stock Performance
The company has a fifty day simple moving average of $0.90 and a two-hundred day simple moving average of $0.77. The company has a market capitalization of $10.59 million, a price-to-earnings ratio of -0.29 and a beta of 0.23.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical?stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
